A synthesized summary of available retrospective studies and one prospective study indicates that the use of SGLT2 inhibitors in oncology patients, particularly those with type 2 diabetes, is associated with a significant reduction in all-cause mortality and heart failure hospitalizations. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.